230 Hemophilias and von Willebrand Disease

REFERENCES

1. Mannucci PM, Tuddenham EG: The hemophilias—from royal genes to gene therapy. *N Engl J Med* 344: 1773, 2001.
2. Hemphill R: Hematologic emergencies and life-threatening bleeding disorders: differential diagnosis, evaluation, and management. *Emerg Med Report* 22: 191, 2001.
3. Keeling D, Tait C, Makris M: Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Center Doctors' Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology. *Haemophilia* 14: 671, 2008.
4. Mannucci PM, Giangrande PL: Choice of replacement therapy for hemophilia: recombinant products only? *Hematol J* 1: 72, 2000.
5. Teitel J, Berntorp E, Collins P, et al: A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. *Haemophilia* 13: 256, 2007.
6. Bjorkman S, Berntorp E: Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. *Clin Pharmacokinet* 40: 815, 2001.
7. Stachnik JM, Gabay MP: Continuous infusion of coagulation factor products. *Ann Pharmacother* 36: 882, 2002.
8. Seremetis SV, Aledort LM: Desmopressin nasal spray for hemophilia A and type I von Willebrand disease. *Ann Intern Med* 126: 744, 1997.
9. Gouw SC, van der Bom JG, Auerswald G, et al: Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. *Blood* 109: 4693, 2007.
10. Warrier I, Ewenstein BM, Koerper MA, et al: Factor IX inhibitors and anaphylaxis in hemophilia B. *J Pediatr Hematol Oncol* 19: 23, 1997.
11. Mannucci PM, Gringeri A, Peyvandi F, et al: Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). *Haemophilia* 13: 65, 2007.
12. Federici AB, Mannucci PM: Advances in the genetics and treatment of von Willebrand disease. *Curr Opin Pediatr* 14: 23, 2002.
13. Budde U, Schneppenheim R: Von Willebrand factor and von Willebrand disease. *Rev Clin Exp Hematol* 5: 335, 2001.
14. Mannucci PM, Federici AB: Management of inherited von Willebrand disease in 2007 *Ann Med* 39: 346, 2007.
15. Nichols WL, Rick ME, Ortel TL, et al: Clinical and laboratory diagnosis of von Willebrand disease: a synopsis of the 2008 NHLBI/NIH guidelines. *Am J Hematol* 84: 366, 2009.
16. Nichols WL, Hultin MB, James AH, et al: von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). *Haemophilia* 14: 171, 2008.
17. Mannucci PM, Federici AB, James AH, Kessler CM: von Willebrand disease in the 21st century: current approaches and new challenges. *Haemophilia* 15: 1154, 2009.

USEFUL WEB RESOURCES

National Hemophilia Foundation—http://www.hemophilia.org
National Heart, Lung, and Blood Institute—http://www.nhlbi.nih.gov/health/dci/Diseases/vWD/vWD_WhatIs.html
American Society of Hematology Clinical Guidelines—http://www.hematology.org/Practice/Guidelines/2934.aspx
British Committee for Standards in Haematology Guidelines (subcommittee of the British Society for Haematology)—http://www.bcshguidelines.com/guidelinesMenu.asp